Premium Subscribers: Complete your KYC to Avoid
Service Suspension. Login Here.

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark Pharma Plunges 4%; BSE HEALTHCARE Index Down 1.3%
Mon, 2 Feb 11:51

Glenmark Pharma Plunges 4%; BSE HEALTHCARE Index Down 1.3%Image source: phive2015/www.istockphoto.com

Glenmark Pharma share price has plunged 4% and is presently trading at Rs 1,857.7.

Meanwhile, the BSE HEALTHCARE index is at 40,575.6 (down 1.3%).

Among the top losers in the BSE HEALTHCARE index today are NARAYANA HRUDAYALAYA (down 3.7%) and ASTER DM HEALTHCARE (down 3.4%).

LAURUS LABS (up 1.4%) and GLAND PHARMA (up 0.1%) are among the top gainers today.

Over the last one year, Glenmark Pharma has moved up from Rs 1,449.4 to Rs 1,857.7, registering a gain of Rs 408.4 (up 28.2%).

On the other hand, the BSE HEALTHCARE index has moved down from 41,619.8 to 40,575.6, registering a loss of 2.5% during the last 12 months.

The top losers among the BSE HEALTHCARE index stocks during this same period were COHANCE LIFESCIENCES (down 65.1%), SYNGENE INTERNATIONAL (down 39.7%) and POLY MEDICURE (down 36.4%).

Live Now: The Small Cap Proxy Players Briefing

What About the Benchmark Indices?

The BSE Sensex is at 80,947.0 (up 0.3%).

The top gainers among the BSE Sensex today are Tata Motors (up 3.3%) and MUNDRA PORT & SEZ (up 3.1%). The most traded stocks in the BSE Sensex are ITC and Tata Steel.

In the meantime, NSE Nifty is at 24,868.1 (up 0.2%). Tata Motors and Tata Consumer Products are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 76,759.8 to 80,947.0, registering a gain of 4,187.2 points (up 5.5%).

Glenmark Pharma Financial Update...

Glenmark Pharma net profit grew 15.9% YoY to Rs 4,032 million for the quarter ended December 2025, compared to a profit of Rs 3,480 million a year ago. Net sales rose 15.1% to Rs 39,006 million during the period as against Rs 33,876 million in October-December 2024.

For the year ended March 2025, Glenmark Pharma reported 157.2% increase in net profit to Rs 10,471 million compared to net loss of Rs 18,309 million during FY24. Revenue of the company grew 12.8% to Rs 133,217 million during FY25.

The current Price to earnings ratio of Glenmark Pharma, based on rolling 12 month earnings, stands at 49.2.


Equitymaster requests your view! Post a comment on "Glenmark Pharma Plunges 4%; BSE HEALTHCARE Index Down 1.3%". Click here!